Berberine can interact with prescription drugs and increase or decrease blood levels of these drugs due to their effects on specific enzymes in the blood. This is especially true for drugs such as metformin metabolized by the liver. There may also be an increased risk of bleeding. An official website of the United States government.
does gov mean it's official. Federal government websites typically end in. Gov or. grand.
Before sharing sensitive information, make sure you are on a federal government site. Pharmacogenetic Research Institute, Institute of Clinical Pharmacology, South Central University, XiangYa School of Medicine, 110 Xiang-Ya Road, Changsha, Hunan 410078, People's Republic of China. Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, 4099 HLSIC; MS1018; 3901 Rainbow Boulevard, Kansas City, KS 66160, USA. UU.
Berberine is a plant alkaloid that is widely used to treat gastrointestinal infections, diabetes, hypertension, and hypercholesterolemia. Many studies have reported interactions between products containing berberine and cytochromes P450 (CYP), but little is known about whether berberine alters CYP activities in humans, especially after repeated doses. A randomized, two-phase crossover clinical study was conducted in healthy male subjects. After 2 weeks of berberine (300 mg, t, i, d.
Repeated administration of berberine (300 mg, t, i, d. Drug interactions should be considered when administering berberine. Half-time plasma concentration profiles and main pharmacokinetic parameters of midazolam, caffeine, omeprazole, dextromethorphan and losartan after 2 weeks of placebo and berberine administration. Data are expressed as mean ± SE.
The circles represent the placebo administration phase and the squares represent the berberine administration phase Pharmacokinetic parameters of the probe drugs in the test and reference periods of a two-phase crossover study. Individual variability was relatively large in the current study, suggesting that the inhibitory effects of berberine could depend on genotype. Other studies with relevant CYP genotypes may be useful to clarify the results. The 0 to 8 hr urinary ratio of dextromethorphan to dextrorphan is a phenotyped marker of CYP2D6 activity, and a dramatic increase in the ratio of parent drug to metabolite indicates that enzyme activity decreases markedly.
Our previous data showed that CYP2D6 plays a key role in berberine metabolism. Therefore, the inhibitory effect of berberine on CYP2D6 activity may be due to substrate competition. CYP2D6 has highly polymorphic enzymatic activity that can result in a dramatic difference in berberine clearance for ultrafast metabolizers, extensive metabolizers and poor metabolizers, so the risk of treatment failure, dose-dependent drug toxicity and drug interactions is of concern when administering berberine. The 0 to 8 hour urinary ratio between losartan and its metabolite E-3174 increased approximately doubled, implying a decrease in CYP2C9 enzyme activity.
Since the above data showed that recombinant human CYP2C9 did not metabolize berberine, an additional study on the regulation of the berberine and CYP2C9 genes may provide evidence to clarify this alteration. CYP1A2 is another important enzyme that metabolizes berberine. Although caffeine AUC0—∞ and Cmax did not fall within the bioequivalence criteria of 80-125%, implying a difference between berberine and controls, changes in caffeine pharmacokinetics were not statistically significant. This discrepancy may be due to the small size of the study sample.
Further studies in larger populations and multiple dose administrations will be useful in confirming and expanding our results, which will guide the use of berberine as a complementary or protective prescription for humans. In the present study, inhibitory effects of berberine against CYP2D6, 3A4 and CYP2C9 were observed, and drug interactions, as well as interethnic variability in berberine metabolism, should be considered when administering berberine or products containing berberine. Conflict of Interest Authors report no conflict of interest. Ying Guo, Pharmacogenetic Research Institute, Institute of Clinical Pharmacology, South Central University, XiangYa School of Medicine, 110 Xiang-Ya Road, Changsha, Hunan 410078, People's Republic of China.
UU. Yao Chen, Pharmacogenetic Research Institute, Institute of Clinical Pharmacology, South Central University, XiangYa School of Medicine, 110 Xiang-Ya Road, Changsha, Hunan 410078, People's Republic of China. Zhi-rong Tan, Pharmacogenetic Research Institute, Institute of Clinical Pharmacology, South Central University, XiangYa School of Medicine, 110 Xiang-Ya Road, Changsha, Hunan 410078, People's Republic of China. Klaassen, Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, 4099 HLSIC; MS1018; 3901 Rainbow Boulevard, Kansas City, KS 66160, USA.
Hong-hao Zhou, Pharmacogenetic Research Institute, Institute of Clinical Pharmacology, South Central University, XiangYa School of Medicine, 110 Xiang-Ya Road, Changsha, Hunan 410078, People's Republic of China. National Library of Medicine8600 Rockville Pike Bethesda, MD 20894 Web Policies FOIAHHS Vulnerability Disclosure. Berberine can interact with metformin and affect blood sugar levels, making it more difficult to control. In one study, joint intake of berberine and metformin led to a 25% drop in the impact of metformin.
The observed changes for midazolam (90% CI of geometric means for the ratio between berberine and control were less than 80% or greater than 125%) suggest non-bioequivalence between the control and berberine treatment phases; in addition, these differences were statistically significant and could also be clinically important. Research has suggested that berberine may help treat diabetes, obesity and inflammation, among other conditions. Berberine sulfate blocks adherence of Streptococcus pyogenes to epithelial cells, fibronectin and hexadecane. Some research suggests that berberine works in a similar way to the drug metformin, which doctors often prescribe to treat type 2 diabetes.
Effects of a Nutraceutical Combination (Berberine, Red Rice Yeast and Policosanols) on Lipid Levels and Endothelial Function, Randomized, Double-Blind, Placebo-Controlled Study. Nutraceutical pill containing berberine versus ezetimibe in the plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment. This supplement has the potential to interact with certain medications and medications, including blood thinners, drugs that lower blood sugar or blood pressure, or medications that act as sedatives. Berberine, or berberine hydrochloride, is a compound in several plants, such as gold seal, barberry, Oregon grape, and tree turmeric.
Eulipidemic Effects of Berberine Administered Alone or in Combination with Other Natural Hypocholesterolemic Agents. Because berberine seems to have similar effects to metformin, it can also be a good treatment option for PCOS. Berberine inhibits the intestinal secretory response of Vibrio cholerae and Escherichia coli enterotoxins. Taking berberine and metformin at the same time does not seem to increase the amount of metformin in the body.
Berberine lowers blood glucose in patients with type 2 diabetes mellitus by increasing insulin receptor expression. . .
